This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Umberto Romeo
Head of R&D at Corden Pharma Caponago


Umberto Romeo has 15+ years of experience in drug product process design, development and manufacturing of chemical and biological compounds throughout all stages of development up to commercialization. He is currently the Head of R&D at Corden Pharma Caponago site leading formulation (including LNP Assembly and Downstream) development, analytical development, validation and industrialization activities for injectable drug products as well as clinical manufacturing operations and MS&T. Prior to his current role, he worked as Project and Alliance Manager in Evotec managing complex projects (from Discovery to Phase 3) to successful completion, covering all phases of the project management process (initiation, planning, execution, monitoring and control, and closure) leading project teams to deliver results within the constraints of schedule.

He worked in UCB as Drug Product Process Design and Development Principal Scientist where he was responsible of CMC development activities of Biopharmaceuticals, with a focus on Drug Product Process Design, Development and Technology Transfer to GMP manufacturing sites. During his mission he established Drug Product Process Design and Development department leading a team of 6 people and supporting the CMC development program of the whole UCB biological pipeline.

He worked in Patheon Inc. as Technology Transfer-Project Manager where he managed successfully the technology transfer of more than 15 drug product manufacturing processes of oral, injectable lyophilized and liquid drug products for European, US, Japanese and ROW markets at Phase 3 /commercial scale into Monza manufacturing plant.

Umberto graduated with a degree in Pharmaceutical Biotechnologies in Milano State University.

Agenda Sessions

  • LNP Formulation Screening, A CDMO Perspective